Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (144)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Gusman, J.
Right arrow Articles by Atassi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gusman, J.
Right arrow Articles by Atassi, G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 22, No. 8, 1111-1117, August 2001
© 2001 Oxford University Press


COMMENTARY

A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol

Julie Gusman,1, Hugues Malonne,2 and Ghanem Atassi,2,3

Laboratoire de Pharmacognosie et Bromatologie (CP205-4) and
2 Laboratoire de Physiologie et Pharmacologie Fondamentales (CP205-7), Institut de Pharmacie, Université Libre de Bruxelles, Campus Plaine, Boulevard du Triomphe, 1050 Brussels, Belgium and
3 Institut de Recherches Servier, 11 Rue des Moulineaux, 92150 Suresnes, France

Resveratrol, a phytoalexin found in grapes and wines, has been reported to exhibit a wide range of pharmacological properties and is believed to play a role in the prevention of human cardiovascular disease (the so-called `French paradox'). This molecule may also play a major role in both cancer prevention and therapy. In this review article we summarize the recent advances that have provided new insights into the molecular mechanisms underlying the promising properties of resveratrol. These include cyclooxygenase, nitric oxide synthase and cytochrome P450 inhibition, as well as cell cycle effects, apoptosis modulation and hormonal activity.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
Z. Yang, S. Yang, B. J. Misner, R. Chiu, F. Liu, and F. L. Meyskens Jr.
Nitric oxide initiates progression of human melanoma via a feedback loop mediated by apurinic/apyrimidinic endonuclease-1/redox factor-1, which is inhibited by resveratrol
Mol. Cancer Ther., December 1, 2008; 7(12): 3751 - 3760.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
P. Jaichander, K. Selvarajan, M. Garelnabi, and S. Parthasarathy
Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin
J. Lipid Res., October 1, 2008; 49(10): 2142 - 2148.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. M. Roccaro, X. Leleu, A. Sacco, A.-S. Moreau, E. Hatjiharissi, X. Jia, L. Xu, B. Ciccarelli, C. J. Patterson, H. T. Ngo, et al.
Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenstrom's Macroglobulinemia
Clin. Cancer Res., March 15, 2008; 14(6): 1849 - 1858.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
N. F. Trincheri, C. Follo, G. Nicotra, C. Peracchio, R. Castino, and C. Isidoro
Resveratrol-induced apoptosis depends on the lipid kinase activity of Vps34 and on the formation of autophagolysosomes
Carcinogenesis, February 1, 2008; 29(2): 381 - 389.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
D. A. Sallman, X. Chen, B. Zhong, D. L. Gilvary, J. Zhou, S. Wei, and J. Y. Djeu
Clusterin mediates TRAIL resistance in prostate tumor cells
Mol. Cancer Ther., November 1, 2007; 6(11): 2938 - 2947.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
B. Lee and S.-K. Moon
Resveratrol Inhibits TNF-{alpha}-Induced Proliferation and Matrix Metalloproteinase Expression in Human Vascular Smooth Muscle Cells
J. Nutr., December 1, 2005; 135(12): 2767 - 2773.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Q. Zhang, X. Tang, Q. Y. Lu, Z. F. Zhang, J. Brown, and A. D. Le
Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1{alpha} and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells
Mol. Cancer Ther., October 1, 2005; 4(10): 1465 - 1474.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
H. Jiang, L. Zhang, J. Kuo, K. Kuo, S. C. Gautam, L. Groc, A. I. Rodriguez, D. Koubi, T. Jackson Hunter, G. B. Corcoran, et al.
Resveratrol-induced apoptotic death in human U251 glioma cells
Mol. Cancer Ther., April 1, 2005; 4(4): 554 - 561.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
J. A. Crowell, P. J. Korytko, R. L. Morrissey, T. D. Booth, and B. S. Levine
Resveratrol-Associated Renal Toxicity
Toxicol. Sci., December 1, 2004; 82(2): 614 - 619.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
C. Gouedard, R. Barouki, and Y. Morel
Induction of the Paraoxonase-1 Gene Expression by Resveratrol
Arterioscler Thromb Vasc Biol, December 1, 2004; 24(12): 2378 - 2383.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Z. Cao, J. Fang, C. Xia, X. Shi, and B.-H. Jiang
trans-3,4,5'-Trihydroxystibene Inhibits Hypoxia-Inducible Factor 1{alpha} and Vascular Endothelial Growth Factor Expression in Human Ovarian Cancer Cells
Clin. Cancer Res., August 1, 2004; 10(15): 5253 - 5263.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Fulda and K.-M. Debatin
Sensitization for Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by the Chemopreventive Agent Resveratrol
Cancer Res., January 1, 2004; 64(1): 337 - 346.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
S. PERVAIZ
Resveratrol: from grapevines to mammalian biology
FASEB J, November 1, 2003; 17(14): 1975 - 1985.
[Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
A. J. Gescher and W. P. Steward
Relationship between Mechanisms, Bioavailibility, and Preclinical Chemopreventive Efficacy of Resveratrol: A Conundrum
Cancer Epidemiol. Biomarkers Prev., October 1, 2003; 12(10): 953 - 957.
[Full Text] [PDF]


Home page
J. Nutr.Home page
J. R. Stewart, M. C. Artime, and C. A. O'Brian
Resveratrol: A Candidate Nutritional Substance for Prostate Cancer Prevention
J. Nutr., July 1, 2003; 133(7): 2440S - 2443.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. D. Ragione, V. Cucciolla, V. Criniti, S. Indaco, A. Borriello, and V. Zappia
p21Cip1 Gene Expression Is Modulated by Egr1: A NOVEL REGULATORY MECHANISM INVOLVED IN THE RESVERATROL ANTIPROLIFERATIVE EFFECT
J. Biol. Chem., June 20, 2003; 278(26): 23360 - 23368.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
A. M. El-Mowafy and M. Alkhalaf
Resveratrol activates adenylyl-cyclase in human breast cancer cells: a novel, estrogen receptor-independent cytostatic mechanism
Carcinogenesis, May 1, 2003; 24(5): 869 - 873.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Banerjee, C. Bueso-Ramos, and B. B. Aggarwal
Suppression of 7,12-Dimethylbenz(a)anthracene-induced Mammary Carcinogenesis in Rats by Resveratrol: Role of Nuclear Factor-{kappa}B, Cyclooxygenase 2, and Matrix Metalloprotease 9
Cancer Res., September 1, 2002; 62(17): 4945 - 4954.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.